A Safety and Effectiveness Study of JNJ-18038683 in Patients With Moderate to Severe Depression
Status:
Completed
Trial end date:
2008-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and effectiveness of JNJ-18038683
compared to escitalopram and placebo in patients with moderate to severe depression.
Phase:
Phase 2
Details
Lead Sponsor:
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.